title: Adrenergic modulation of migration, CD11b and CD18 expression, ROS and interleukin-8 production by human polymorphonuclear leukocytes.
abstract: OBJECTIVE
  Adrenergic modulation of immunity has been extensively characterized, however, few information exist regarding polymorphonuclear leukocytes (PMN), despite their key role in immunity and inflammation. We investigated the effect of adrenergic agents on human PMN migration, CD11b and CD18 expression, reactive oxygen species (ROS) and interleukin (IL)-8 production, and on adrenoceptor (AR) expression.
  
  
  METHODS
  Migration was measured by the Boyden chamber assay, CD11b/CD18 expression was assessed by flow cytometry, intracellular ROS were detected by spectrofluorimetry, and IL-8 was quantitated by standard ELISA assay. AR mRNA levels were measured by real-time PCR and PMN morphology was studied by scanning electron microscopy.
  
  
  RESULTS
  Adrenaline(A), noradrenaline and the β-AR agonist isoprenaline reduced N-formyl-Met-Leu-Phe (fMLP)-induced migration, CD11b/CD18 expression, and ROS production, without affecting IL-8. The effect of A on CD11b was antagonized by yohimbine and propranolol, and increased by prazosin. The effect on ROS production was completely abolished by propranolol. PMN expressed α(1A)-, α(1B)-, α(1D)-, α(2A)-, α(2C)-, β(1)-, β(2)-, and β(3)-AR mRNA. A prevented fMLP-induced morphological changes of PMN.
  
  
  CONCLUSIONS
  Adrenergic agents reduced PMN responses mainly through β-AR, although α-AR may contribute at least to CD11b expression. AR-operated pathways in PMN should be investigated in disease conditions and in the response to therapeutic agents.
authors.affiliation: Center for Research in Medical Pharmacology, University of Insubria, Via Ottorino Rossi n.9, 21100, Varese VA, Italy, angela.scanzano@uninsubria.it.
authors.forename: Angela
authors.initials: A
authors.lastname: Scanzano
authors.forename: Laura
authors.initials: L
authors.lastname: Schembri
authors.forename: Emanuela
authors.initials: E
authors.lastname: Rasini
authors.forename: Alessandra
authors.initials: A
authors.lastname: Luini
authors.forename: Jessica
authors.initials: J
authors.lastname: Dallatorre
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Legnaro
authors.forename: Raffaella
authors.initials: R
authors.lastname: Bombelli
authors.forename: Terenzio
authors.initials: T
authors.lastname: Congiu
authors.forename: Marco
authors.initials: M
authors.lastname: Cosentino
authors.forename: Franca
authors.initials: F
authors.lastname: Marino
mesh_terms: D018674:Adrenergic Antagonists / Q000494:pharmacology*; D039481:CD11b Antigen / Q000378:metabolism; D018821:CD18 Antigens / Q000378:metabolism; D002465:Cell Movement / Q000187:drug effects; D002478:Cells, Cultured; D015870:Gene Expression; D006801:Humans; D016209:Interleukin-8 / Q000378:metabolism; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D011224:Prazosin / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D017382:Reactive Oxygen Species / Q000378:metabolism; D011941:Receptors, Adrenergic / Q000235:genetics; D015016:Yohimbine / Q000494:pharmacology
chemical_list: D018674:Adrenergic Antagonists; D039481:CD11b Antigen; D018821:CD18 Antigens; C508606:CXCL8 protein, human; C509295:ITGAM protein, human; D016209:Interleukin-8; D017382:Reactive Oxygen Species; D011941:Receptors, Adrenergic; D015016:Yohimbine; D009240:N-Formylmethionine Leucyl-Phenylalanine; D011433:Propranolol; D011224:Prazosin